Please select a community
Automation & Microfluidics
Biologics & Bioprocessing
Chemical Process Scale Up
Food & Beverage Analysis
Forensic Science & Clinical Toxicology
Genotyping & Gene Expression
LIMS & ELNs
Metabolomics & Lipidomics
Molecular & Clinical Diagnostics
Next Gen Sequencing
Stem Cells, Cellular Therapy & Biobanking
Become a Member
Add My Services
Chemcap Clearview Cabinets are Easy to Assemble
Thursday, May 14, 2015
Bigneat knows that not everyone takes naturally to the idea of ‘do-it-yourself’. However, the easy-to-follow instructions and detailed diagrams in their new ‘Shortform User Manual’ show how easy it is to self-assemble your own ductless fume cabinet, whether you’re a flat-pack furniture novice or ‘build-your-own’ virtuoso.
Catalent Launches ADVASEPT™ Lock Delivery Technology
Friday, April 24, 2015
Company announces the expansion of its advanced, aseptic, glass-free injectable platform.
Rentschler Expands European Manufacturing Capabilities
Thursday, April 16, 2015
Companies celebrate handover of 1000th ÄKTAprocess.
A New Test to Simultaneously Detect 22 Respiratory Pathogens
Tuesday, April 07, 2015
Luminex® Corporation launches the NxTAG™ Respiratory Pathogen Panel (RUO) - A closed-tube, flexibly scalable solution for respiratory testing.
Expert System Optimizes Discovery of Drugs
Tuesday, April 07, 2015
Pharmaceutical companies use the expert system IMPACT-F to forecast drug-uptake in humans.
High ThroughputPARP in vivo Pharmacodynamic Assay
Monday, February 23, 2015
AMSBIO has introduced a unique High Throughput PARP in vivo Pharmacodynamic Assay that can be used to monitor the efficacy of poly-ADP-ribose polymerase (PARP) inhibitors on PAR formation in vivo; and to measure drug action on PARP in both in vivo and in vitro settings.
Vetter Development Service Chicago is Now Ready for Realizing Clinical Syringe Projects
Friday, December 12, 2014
Recent facility expansion offers new manufacturing options and additional filling capacity.
Imperial Innovations Leads £50 Million Series B Funding Round in Cell Medica
Tuesday, November 25, 2014
Cell Medica will use the investment capital to progress further the development of cellular immunotherapy products.
Clustering Effect Translates into Major Growth for BioPharma Specialist
Saturday, October 25, 2014
Company manages translation and linguistic validation projects.
Showing Results 21 - 30 of 323
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Advertise On This Site
Terms & Conditions
©2016 Technology Networks
, all rights reserved.
Latest presentations and webinars
3,000+ scientific and medical posters
4,400+ scientific videos
JOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!